Barrett’s esophagus with high grade dysplasia is associated with non-esophageal cancer

Table 2 Overall cancer cases, stratified to pre-study and incident cases n (%)

	Pre-study cancers	Incident cancers	Lifetime cancers
Esophagus	2 (0.5)2	4 (1)	6 (1.6)
Cardia	2 (0.5)	3 (0.8)	5 (1.3)
Stomach	3 (0.8)	0 (0)	3 (0.8)
Colorectal cancer	9 (2.3)	1 (0.3)	10 (2.6)
Small intestine	1 (0.3)	0 (0)	1 (0.3)
Cholangiocarcinoma	1 (0.3)	0 (0)	1 (0.3)
Pancreas	0 (0)	2 (0.5)	2 (0.5)
Bladder	5 (1.3)	4 (1)	9 (2.3)
Prostate	11 (2.8)	0 (0)	11 (2.8)
Kidney	2 (0.5)	2 (0.5)	4 (1)
Hematologic cancer	8 (2.07)	4 (1)	12 (3.1)
Skin	4 (1)	2 (0.5)	6 (1.6)
Breast	4 (1)	2 (0.5)	6 (1.6)
Thyroid	3 (0.8)	0 (0)	3 (0.8)
Lung	0 (0)	2 (0.5)	2 (0.5)
Kaposi	0 (0)	1 (0.3)	1 (0.3)
Laryngeal	3 (0.8)	0 (0)	3 (0.8)
Cervical	1 (0.3)	0 (0)	1 (0.3)
Any type of cancer	59 (15.3)	27 (7)	86 in 75 (19.4) patients1
BE cancer	3 (0.8)	7 (1.8)	10 in 10 (2.6) patients
Non-BE cancers	56 (14.5)	20 (5.2)	76 in 65 (16.8) patients

¹There were 9 patients with 2 lifetime cancers, and one with 3 cancer cases;

²One patient had a pre-study diagnosis of esophageal squamous cell carcinoma (thus, not counted as BE related and not included in the outcome analysis for non-BE cancer free survival). BE: Barrett’s esophagus.